Syneos Health

NCT00766363

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

NCT01034748

A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers

NCT01258816

The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)

NCT01405950

Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy

NCT01383096

Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers

NCT01714037

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]

NCT01746901

A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers

NCT01775189

A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted

NCT01803308

A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection

NCT01919554

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents

NCT02508740

Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment

NCT02022163

Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.

NCT02588105

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

NCT02636036

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

NCT02914353

Study to Evaluate Safety, PK and PD of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects

NCT02935790

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

NCT03164109

A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers

NCT03194139

A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers

NCT03291002

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

NCT03337126

Bioavailability of ATI-1501 With Taste Test Sub Study

NCT03416816

A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

NCT04018664

Oral Abuse Potential Study of Nalbuphine

NCT04020016

Nalbuphine ER Effects of Liver Disease on Pharmacokinetics and Itch

NCT03765671

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

NCT03776539

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

NCT03844191

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

NCT04021563

The Safety, Tolerability, Pharmacokinetics(PK) of SR419 in Healthy Volunteers

NCT04068259

Single Ascending Dose Study of PBI-4547 in Healthy Subjects

NCT04495933

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

NCT04631562

Study of ALXN1820 in Healthy Adult Participants

NCT04764851

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

NCT04706962

TH1902 in Patients With Advanced Solid Tumors

NCT04730804

A Study of ALXN1830 in Healthy Adult Participants

NCT04887038

First-in-Human Study of SRT-015 in Healthy Subjects.

NCT04902105

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

NCT04885829

Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers

NCT04925050

First-in-Human Study of VB0004 in Healthy Subjects and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk

NCT04893512

First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects

NCT04993443

First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

NCT05088369

Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201

NCT05278845

Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects

NCT05053334

Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair

NCT05363839

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

NCT05382819

A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis

NCT04879589

Phase 1 Study of ATRS-2002 in Healthy Male Adults

NCT05310487

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects

NCT05625334

Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.

NCT05715736

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3

NCT05625347

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

NCT05807971

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects

NCT05896969

Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

NCT06170827

Study to Evaluate the AIO-001 in Healthy Participants

NCT06194864

Drug Interaction Study

NCT06204250

A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers

NCT06435039

A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers

NCT06780254

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of Single- and Multiple-Ascending Doses of MH-001 in Healthy Volunteers